By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aldeyra Therapeutics 

131 Hartwell Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-761-4904 Fax: N/A


SEARCH JOBS

Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, NS2, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.

YEAR FOUNDED:

2004

LEADERSHIP:

FOUNDERS: Thomas A. Jordan and John E. Dowling

CEO: Todd C. Brady

CMO: David J. Clark

CFO: Stephen Tulipano

JOB OPPORTUNITY:

Please click here for Aldeyra job opportunities..

CLINICAL TRIAL:

Please click here for clinical trial information..


Key Statistics


Email: dburke@theruthgroup.com
Ownership: Public

Web Site: Aldeyra
Employees:
Symbol: ALDX
 




Segment
Biotechnology





Company News
Aldeyra (ALDX) Announces Pricing Of Public Offering Of Common Stock 9/19/2017 8:09:41 AM
Aldeyra (ALDX) Announces Proposed Public Offering Of Common Stock 9/19/2017 7:49:24 AM
Aldeyra (ALDX) Announces Positive Results From Dry Eye Disease Phase IIa Clinical Trial 9/12/2017 6:05:55 AM
Aldeyra (ALDX) Announces Second Quarter 2017 Financial Results 8/8/2017 12:29:07 PM
Aldeyra (ALDX) Schedules Webcast And Conference Call To Provide Second Quarter 2017 Financial Results 8/1/2017 2:11:12 PM
Aldeyra (ALDX) Announces Last Patient Dosed In Dry Eye Disease Phase IIa Clinical Trial 7/18/2017 6:45:37 AM
Aldeyra (ALDX) To Present Novel Data On The Anti-Inflammatory Mechanism And Activity Of ADX-102 At The World Congress On Inflammation 2017 Annual Meeting 6/19/2017 6:15:53 AM
Aldeyra (ALDX) Schedules Conference Call And Webcast To Announce Results From Allergic Conjunctivitis Phase IIb Clinical Trial 6/14/2017 8:14:31 AM
Aldeyra (ALDX) Plummets As Eye Drug Misses Primary Endpoint In Phase IIb Test 6/14/2017 6:27:01 AM
Aldeyra (ALDX) Announces First Patient Enrolled In Dry Eye Disease Phase IIa Clinical Trial 6/6/2017 8:26:53 AM
123456789
//-->